[go: up one dir, main page]

MX2019004238A - Composiciones farmaceuticas liofilizadas para suministro vaginal. - Google Patents

Composiciones farmaceuticas liofilizadas para suministro vaginal.

Info

Publication number
MX2019004238A
MX2019004238A MX2019004238A MX2019004238A MX2019004238A MX 2019004238 A MX2019004238 A MX 2019004238A MX 2019004238 A MX2019004238 A MX 2019004238A MX 2019004238 A MX2019004238 A MX 2019004238A MX 2019004238 A MX2019004238 A MX 2019004238A
Authority
MX
Mexico
Prior art keywords
dosage form
pharmaceutical compositions
lyophilized pharmaceutical
vaginal delivery
weight
Prior art date
Application number
MX2019004238A
Other languages
English (en)
Other versions
MX384337B (es
Inventor
Masto Emilie
Garrett Lisa
Barrat Niamh
Teng Wong Yik
Theresa Mclaughlin Rosaleen
Gerrard BANBURY Susan
Original Assignee
Catalent Uk Swindon Zydis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Uk Swindon Zydis Ltd filed Critical Catalent Uk Swindon Zydis Ltd
Publication of MX2019004238A publication Critical patent/MX2019004238A/es
Publication of MX384337B publication Critical patent/MX384337B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una forma de dosificación vaginal liofilizada sólida que puede tener una cantidad efectiva de al menos un ingrediente activo, un agente que forma estructura cristalina en una cantidad de aproximadamente 5 % en peso hasta aproximadamente 40 % en peso, con base en el peso total de la forma de dosificación liofilizada, y al menos un agente que forma matriz mucoadhesiva polimérica. La forma de dosificación puede tener un pH de aproximadamente 4.0 hasta 5.0, y puede desintegrarse dentro de 120 segundos después de ser puesta en contacto con una mucosa vaginal. También se describe un método para suministrar un ingrediente activo a la mucosa vaginal usando la forma de dosificación sólida descrita.
MX2019004238A 2016-10-13 2017-10-13 Composiciones farmacéuticas liofilizadas para suministro vaginal. MX384337B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407709P 2016-10-13 2016-10-13
PCT/IB2017/056373 WO2018069888A1 (en) 2016-10-13 2017-10-13 Lyophilized pharmaceutical compositions for vaginal delivery

Publications (2)

Publication Number Publication Date
MX2019004238A true MX2019004238A (es) 2019-11-08
MX384337B MX384337B (es) 2025-03-14

Family

ID=60320930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004238A MX384337B (es) 2016-10-13 2017-10-13 Composiciones farmacéuticas liofilizadas para suministro vaginal.

Country Status (9)

Country Link
US (1) US11026883B2 (es)
EP (1) EP3525765A1 (es)
JP (1) JP7219712B2 (es)
CN (1) CN110267652A (es)
AU (1) AU2017342160A1 (es)
CA (1) CA3040422A1 (es)
MX (1) MX384337B (es)
RU (1) RU2753864C2 (es)
WO (1) WO2018069888A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
JP7424636B2 (ja) 2017-10-06 2024-01-30 ジェディア バイオテック エービー 微生物感染症の治療および／または予防用グルコン酸誘導体
MX2020014000A (es) 2018-06-27 2021-06-15 Bioxcel Therapeutics Inc Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
MX2021004553A (es) * 2018-10-23 2021-07-16 Eastern Virginia Medical School Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN116194085A (zh) * 2020-09-17 2023-05-30 康特伦英国斯温顿捷迪斯有限公司 基于表面活性剂与高分子量鱼明胶的剂型用于改善流动特性的用途
EP4243796A4 (en) 2020-11-16 2025-01-22 Orcosa Inc. IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN112353933B (zh) * 2020-12-14 2021-09-24 黑龙江中医药大学 一种预防和/或治疗子宫肌瘤的药物及其制备方法
WO2023204734A1 (ru) 2022-04-21 2023-10-26 Общество С Ограниченной Ответственностью "Кинетик-Фарм" Средство для интравагинальной доставки активного компонента, способ получения и применения средства
CN115656526B (zh) * 2022-12-22 2023-07-04 北京水木济衡生物技术有限公司 糖化血红蛋白质控品的制备方法、复溶装置和复溶剂
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5417224A (en) * 1993-05-19 1995-05-23 Advanced Medical Instruments, Inc. Tampon and method for manufacturing the same
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
GB9504201D0 (en) 1995-03-02 1995-04-19 Scherer Ltd R P Process for the preparation of a solid pharmaceutical dosage form
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
CA2239199A1 (en) 1997-06-11 1998-12-11 Eric Segal Microwaveable confection mold and method of using same
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
BR0007360A (pt) * 1999-12-23 2001-08-14 Johnson & Johnson Composição de liberação controlada
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US20040156894A1 (en) * 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
EP2679222A1 (en) * 2007-03-30 2014-01-01 Laccure Ab Use of oligomers of lactic acid in the treatment of gynaecological infections
WO2009153634A1 (en) * 2008-06-19 2009-12-23 University Of Witwatersrand, Johannesburg A transmucosal delivery system
EP2174650A1 (en) * 2008-10-08 2010-04-14 Polichem SA Modified release emulsions for application to skin or vaginal mucosa
SG172136A1 (en) * 2008-12-17 2011-07-28 Sato Pharma A disintegrating tablet
US10548839B2 (en) * 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
EP2704694A4 (en) 2011-05-02 2014-11-19 Aptalis Pharmatech Inc RAPID DISSOLUTION TABLET COMPOSITIONS FOR VAGINAL DELIVERY
CN102784120B (zh) * 2012-08-23 2014-03-26 海南卫康制药(潜山)有限公司 甲硝唑组合物阴道冻干崩解片及其制备方法
JP6341777B2 (ja) * 2014-06-30 2018-06-13 リプリーズ バイオファーマシューティクス，エルエルシー 低用量デスモプレシンを含有する医薬組成物

Also Published As

Publication number Publication date
CN110267652A (zh) 2019-09-20
JP2019532109A (ja) 2019-11-07
AU2017342160A1 (en) 2019-05-23
CA3040422A1 (en) 2018-04-19
RU2753864C2 (ru) 2021-08-24
MX384337B (es) 2025-03-14
US20190314274A1 (en) 2019-10-17
US11026883B2 (en) 2021-06-08
EP3525765A1 (en) 2019-08-21
WO2018069888A1 (en) 2018-04-19
RU2019113770A (ru) 2020-11-17
RU2019113770A3 (es) 2021-01-26
JP7219712B2 (ja) 2023-02-08

Similar Documents

Publication Publication Date Title
MX2019004238A (es) Composiciones farmaceuticas liofilizadas para suministro vaginal.
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
PE20091184A1 (es) Formas de dosificacion farmaceutica
ES2572157T3 (es) Composiciones en forma de partículas para la administración de fármacos poco solubles
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
BRPI0414254B8 (pt) composição farmacêutica compreendendo hcl de cinacalceto
UY30535A1 (es) Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
BR112012023324B8 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
CO2019008053A2 (es) Agente terapéutico para enfermedades del hígado
CL2011001131A1 (es) Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp)
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
PE20150762A1 (es) Formulaciones de etanercept que muestran una marcada reduccion de la cantidad de particulas subvisibles
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
MX393613B (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
BR112014009438A2 (pt) composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral
MY197464A (en) Aza-indazole compounds for use in tendon and/or ligament injuries
BR112016024020A8 (pt) composição farmacêutica
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
AR062925A1 (es) Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
BR112018016545A2 (pt) formulação farmacêutica liofilizada e seu uso
CR20150508A (es) Formulaciones veterinarias estables de combinación de lactonas macrocíclicas e imidazotiazoles
MX2020003697A (es) Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas.
CO6390100A2 (es) Composiciones con liberación rápida de fármaco